{"id":"spm-907","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Atrioventricular block"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Macular edema"}]},"_chembl":{"chemblId":"CHEMBL5841751","moleculeType":null,"molecularWeight":"464.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking sphingosine-1-phosphate receptor 1 (S1P1) on lymphocytes, SPM 907 prevents their migration from lymph nodes and spleen into peripheral blood and target tissues. This mechanism reduces pathogenic immune cell infiltration into affected organs. The drug is being developed for autoimmune and inflammatory conditions where lymphocyte-mediated tissue damage is a key pathogenic driver.","oneSentence":"SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:20.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT00220402","phase":"PHASE3","title":"Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00220376","phase":"PHASE3","title":"Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-04","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00220389","phase":"PHASE2","title":"Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-06","conditions":"Overactive Bladder","enrollment":""},{"nctId":"NCT00220363","phase":"PHASE3","title":"A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-01","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00138723","phase":"PHASE3","title":"Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Overactive Bladder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPM 907","genericName":"SPM 907","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts. Used for Ulcerative colitis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}